CRISM Therapeutics trades just above 10p placing level ahead of key ChemoSeed trial update
CRISM Therapeutics Corporation closed out last week trading a touch over 10p, the same price as its most recent fundraising. Investors looked at a modest move up in the AIM-listed shares as new details came out on ownership and options ahead of a clinical trial site update expected later this month. London markets didn’t open Sunday. AJ Bell last quoted CRISM at 10.50p, up 1.00p or 10.53%, with volume at 1,043,387 shares. The broker’s site listed a 10.00p sell price and 11.00p buy price. Shares opened at 9.50p and hit a 10.48p session high. Market cap stood at £8.31 million. On July 3, the same feed had the FTSE AIM All Share off 0.17%.